Together, these findings argue for further investigation of rationally designed multi-antigen, antibody-eliciting malaria vaccines or mAb prophylactics that target multiple antigens and might include CSP as well as non-CSP targets such as TRAP. This evidence concerns the gene DNAJC5 and malaria.